TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Gillette Functional Walking Assessment Questionnaire (FAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pediatric Functional Independence Scale (WeeFIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Scores of TCM clinical symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical scoring system of Toronto (TCSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoroscopy time needed to implant a CIED
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peak skin dose of radiation exposure during CIED implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation exposure (kerma-area product) during CIED implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Immune thrombocytopenia (ITP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of AIHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change From Baseline for Urinary Total NNAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of angiographic no-reflow/slow-reflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health status (Seattle Angina Score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: protein carbonyl concentration in the tracheal aspirate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Assessment of Chronic Illness Care (PACIC)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Compassionate engagement and action scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Work and social adjustment scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Self-efficacy for managing chronic disease scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose (MTD) of irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Bacterial Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in PANSS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital signs (e.g., blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total amount of administered radioactivity recovered in excreta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-hour systolic Ambulatory Blood Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of Omarigliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Omarigliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Total Body Clearance (CL/F) of Omarigliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: External cephalic version success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Complete histologic polyp eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Women Undergoing Cesarean Section for Fetal Intolerance of Labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Composite of all-cause death, myocardial infarction, stent thrombosis, and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Migration of the tibial component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in the Clinical Global Impression - Severity of Illness subscale (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in Lipopolysaccharide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Self-Care of Heart Failure Index (SCHFI) maintenance subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life measured by SF-36v2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life measured by PGWBI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cobb Angle (Visit 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cobb Angle (Visit 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Italian Spine Youth Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants with Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Zonulin concentration in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final protein/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of all reported Serious Adverse Events (SAEs) and all procedure- or device-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Apnea-Hypopnea Index from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the quality of life measured by the Functional Outcomes of Sleep Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Permanent Product Measure of Performance (PERMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exacerbation rate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Grade IIb or Higher Histolopathologic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PrEP Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in best corrected visual acuity (VA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global ketone (11C-AcAc) uptake in grey matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma ketone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorbed dose per Organ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Electronic Caliper Spinal Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in crestal bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain intensity measured by Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ongoing pregnancy beyond the 20th gestational week rate
Endpoint domain: Mortality/survival
Primary endpoint: Normalization or reduction in prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of subjects achieving post-vaccination serum antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CT coronary angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Phase Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in A1C (%) at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Experiencing An Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of PMZ-1620 related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients not receiving full treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from Baseline in executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in cortical thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tremor Motor Score Percent Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Device and Procedure Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to normalization of body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of L-Serine
Endpoint domain: Adverse events/effects
Primary endpoint: Synchrony and patient effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total BEHAVE-AD score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Duration of use of hybrid closed-loop (HCL) system
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidences of Appropriate Therapies (ATP and Shocks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ICD-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Device-oriented composite end point (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the magnitude of DVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final Cure six months after the end of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Overall seroprevalence of SARS-Cov-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of subjects who have died at 30 days post treatment
Endpoint domain: Mortality/survival
Primary endpoint: Number of subjects who experience a Major Adverse Event at 30 days post treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Urination function recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of patients with gastroduodenal erosions and ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Trail Making Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plate Tapping Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ruler-drop test (Ditrich's test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in markers of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glycaemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freedom from unanticipated serious adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: Need for ongoing intravitreal aflibercept injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bacteriological eradication of the initial pathogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Assessment of psycho-emotional factors and stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reducers
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Change in Indoxyl Sulfate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Average weekly hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemoglobin change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain intensity - Numerical Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity - Pressure pain threshold (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone union and callus formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail and screws resistance over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rhinitis auto questionnaire symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relative Bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving target hemoglobin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aorta diameter in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to a 50% Reduction in Reported Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of white matter lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Classification of white matter lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurocognitive Function Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to first attack after completion of pulse regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intensity of attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variation in signal during language task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe neurodevelopmental impairment
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Curve (AUC) for the Oral Mucositis Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Grade 2 Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Grade 3 Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Estimated Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prediction of impending preterm birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: SARS-CoV-2 antibodies (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive PCR test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in high sensitivity troponin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Physical Examination Abnormalities at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Physical Examination Abnormalities at Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Medical History at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Medical History at Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified sulcus Bleeding Index changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morgan and Russell score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinical laboratory test abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with vital signs abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Stress Scale - PSS-10
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain reduction assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular diseases markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Taste Detection Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Potential Clinically Significant (PCS) changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Potential Clinically Significant (PCS) changes in physical exams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wrinkle Severity Rating Scale (WSRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Who Develop Major Depression and Anxiety Disorders
Endpoint domain: Adverse events/effects
Primary endpoint: General Health Questionnaire (GHQ) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Plasma Triglycerides at 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma high density lipoprotein cholesterol at 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma glucose at 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Maximum Central Keratometry (Kmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Best Corrected Distance Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLIE 8 questionnaire results
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in Subcutaneous Adipose Tissue Volume at Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Visceral Adipose Tissue Volume at Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Presence of Brown Adipose Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Abdominal Musculature Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MYCN/control ratio cutoff for neuroblastoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MRI precision in delimitation of circumferential resection margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: histopathological response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and tolerability of FP-025
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of hilar stricture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteomic pattern changes of CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events from time of index procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects who died
Endpoint domain: Mortality/survival
Primary endpoint: Changes in the number of days with moderate/intense migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in mean 24-hour systolic and diastolic ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of subjects who reach systolic blood pressure goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in estimated glomerular filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in skin rash
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants with abnormal clinical assessment and/or laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sniff Nasal Inspiratory Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and tolerability of MK2461
Endpoint domain: Adverse events/effects
Primary endpoint: Fluorescent uptake values (FUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of success (yes or no)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall diagnostic precision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Miscarriage
Endpoint domain: Mortality/survival